[go: up one dir, main page]

HUE067584T2 - Eljárások paliperidon-palmitát formulációk reszuszpenziójának biztosítására - Google Patents

Eljárások paliperidon-palmitát formulációk reszuszpenziójának biztosítására

Info

Publication number
HUE067584T2
HUE067584T2 HUE21210307A HUE21210307A HUE067584T2 HU E067584 T2 HUE067584 T2 HU E067584T2 HU E21210307 A HUE21210307 A HU E21210307A HU E21210307 A HUE21210307 A HU E21210307A HU E067584 T2 HUE067584 T2 HU E067584T2
Authority
HU
Hungary
Prior art keywords
resuspension
ensuring
methods
paliperidone palmitate
formulations
Prior art date
Application number
HUE21210307A
Other languages
English (en)
Inventor
Peter D'hoore
Ignace Wallaert
Jimmy Nguyen
Frank Meeussen
Srihari Gopal
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=78789763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE067584(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HUE067584T2 publication Critical patent/HUE067584T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/21—General characteristics of the apparatus insensitive to tilting or inclination, e.g. spill-over prevention
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/06—Packaging for specific medical equipment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE21210307A 2020-11-30 2021-11-24 Eljárások paliperidon-palmitát formulációk reszuszpenziójának biztosítására HUE067584T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063119305P 2020-11-30 2020-11-30
US202163237883P 2021-08-27 2021-08-27

Publications (1)

Publication Number Publication Date
HUE067584T2 true HUE067584T2 (hu) 2024-10-28

Family

ID=78789763

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE21210307A HUE067584T2 (hu) 2020-11-30 2021-11-24 Eljárások paliperidon-palmitát formulációk reszuszpenziójának biztosítására

Country Status (19)

Country Link
US (2) US11666697B2 (hu)
EP (2) EP4424369A3 (hu)
JP (1) JP2023551007A (hu)
KR (1) KR20230116008A (hu)
CN (1) CN116528837B (hu)
AU (1) AU2021388842A1 (hu)
CA (1) CA3203567A1 (hu)
DK (1) DK4005555T3 (hu)
ES (1) ES2983033T3 (hu)
FI (1) FI4005555T3 (hu)
HR (1) HRP20240689T1 (hu)
HU (1) HUE067584T2 (hu)
IL (1) IL303254A (hu)
LT (1) LT4005555T (hu)
MX (1) MX2023006369A (hu)
PL (1) PL4005555T3 (hu)
PT (1) PT4005555T (hu)
RS (1) RS65612B1 (hu)
WO (1) WO2022112367A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023551009A (ja) 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ．ベー． 持続放出パリペリドン注射可能製剤に関連する投与レジメン
HRP20240086T1 (hr) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US9439906B2 (en) 2007-12-19 2016-09-13 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
HRP20240022T1 (hr) 2015-04-07 2024-03-29 Janssen Pharmaceutica Nv Režim za doziranje propuštenih doza injektibilnih estera paliperidona s produljenim djelovanjem
WO2016199170A2 (en) 2015-06-10 2016-12-15 Cipla Limited Paliperidone palmitate particles and compositions thereof
JP6668387B2 (ja) 2015-06-19 2020-03-18 ヤンセン ファーマシューティカ エヌ．ベー． 薬物の投与及び混合のための装置及び方法、並びにそのための適切な技法のトレーニング
US20220062557A1 (en) 2020-09-02 2022-03-03 Janssen Pharmaceutica Nv Pre-filled syringe with optimized stopper placement
JP2023551009A (ja) 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ．ベー． 持続放出パリペリドン注射可能製剤に関連する投与レジメン
LT4025188T (lt) 2020-11-30 2024-03-12 Janssen Pharmaceutica Nv Dozavimo režimai susiję su prailginto atpalaidavimo paliperidono injekcinėmis vaisto formomis
HRP20240086T1 (hr) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem

Also Published As

Publication number Publication date
AU2021388842A9 (en) 2025-03-13
PL4005555T3 (pl) 2024-09-02
CN116528837B (zh) 2025-03-14
US20220168497A1 (en) 2022-06-02
AU2021388842A1 (en) 2023-07-13
RS65612B1 (sr) 2024-07-31
LT4005555T (lt) 2024-06-25
CA3203567A1 (en) 2022-06-02
ES2983033T3 (es) 2024-10-21
HRP20240689T1 (hr) 2024-08-30
WO2022112367A1 (en) 2022-06-02
MX2023006369A (es) 2023-08-09
US11666697B2 (en) 2023-06-06
CN116528837A (zh) 2023-08-01
IL303254A (en) 2023-07-01
EP4005555A1 (en) 2022-06-01
EP4424369A2 (en) 2024-09-04
KR20230116008A (ko) 2023-08-03
EP4005555B1 (en) 2024-05-15
FI4005555T3 (fi) 2024-06-18
EP4424369A3 (en) 2024-12-11
DK4005555T3 (da) 2024-05-27
PT4005555T (pt) 2024-05-23
US20230241304A1 (en) 2023-08-03
JP2023551007A (ja) 2023-12-06

Similar Documents

Publication Publication Date Title
RS65612B1 (sr) Metodi za osiguravanje resuspenzije formulacija paliperidon palmitata
HK1247822A1 (zh) 用於活性劑口服給藥的製劑
IL284631A (en) Mesoporous silica particles compositions for viral delivery
IL260263A (en) Safety controls for a network connected autonomous vehicle
IL273852A (en) Preparation and storage of liposomal RNA formulations suitable for treatment
HK1200716A1 (en) Methods for treating cancers using oral formulations of cytidine analogs
EP2661273A4 (en) IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
IL264880A (en) Preparations for oral administration of active substances
SG11202006080SA (en) Liquid oral formulations for pde v inhibitors
EP2575765A4 (en) MUSEPRAYFORMULATIONS AND METHOD FOR THE ADMINISTRATION OF SILDENAFIL
ZA201908454B (en) Solid preparation of cariprazine for oral administration
IL271777A (en) Preparations for intravenous administration of medical substances
ZA201403195B (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
SI3768284T1 (sl) Sestavki iz flagelina enterococcusa za uporabo v terapiji
IL259952A (en) Use of tryptophan derivatives for protein formulations
ZA202006264B (en) Stable formulations of therapeutic antibody
HK1199843A1 (en) Oral spray formulations and methods for administration of sildenafil
PT3524260T (pt) Composições farmacêuticas para o tratamento de inapetência
IL283286A (en) Pharmaceutical formulations of cyclosporine analogs
EP3525772A4 (en) FORMULATIONS FOR THE ENTERIC ADMINISTRATION OF THERAPEUTIC AGENTS
IL313865A (en) Lipid-based formulations for administration of RNA
IL317940A (en) The highly soluble forms of harmine
GB202110139D0 (en) Performance-tuned formulations of piperonly derivatives and methods for their preparation
HK1202451A1 (en) Therapeutic compositions for intranasal administration of zolpidem
IL310652A (en) Radiprodil formulations